IMA Advisory Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.29K Buy
422
+117
+38% +$452 ﹤0.01% 738
2025
Q4
$1.25K Buy
+305
New +$1.51K ﹤0.01% 749

Other funds holding RXRX

IMA Advisory Services's RXRX Position: Q1 2026 in Review

IMA Advisory Services increased its Recursion Pharmaceuticals (RXRX) stake by 38% in Q1 2026, buying an estimated $452 and bringing the position to 422 shares worth $1.29K. The position accounts for ﹤0.01% of the portfolio, ranked #738.

IMA Advisory Services first reported a position in RXRX in Q4 2025 and has held it in 2 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • IMA Advisory Services held 422 shares of Recursion Pharmaceuticals worth $1.29K as of Q1 2026.
  • IMA Advisory Services bought 117 Recursion Pharmaceuticals shares in Q1 2026, an estimated $452.
  • Recursion Pharmaceuticals made up ﹤0.01% of IMA Advisory Services's portfolio in Q1 2026, its #738 holding.
  • IMA Advisory Services first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on IMA Advisory Services's 13F filing for Q1 2026, filed 6 May 2026.